1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Drugs In Development, 2022, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 103, 105, 5, 16, 246, 61 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 14, 1, 58 and 10 molecules, respectively.
Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Glioblastoma Multiforme (GBM) - Overview
- Glioblastoma Multiforme (GBM) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glioblastoma Multiforme (GBM) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
- Glioblastoma Multiforme (GBM) - Drug Profiles
- Glioblastoma Multiforme (GBM) - Dormant Projects
- Glioblastoma Multiforme (GBM) - Discontinued Products
- Glioblastoma Multiforme (GBM) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Glioblastoma Multiforme (GBM), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Glioblastoma Multiforme (GBM) - Dormant Projects, 2022
- Glioblastoma Multiforme (GBM) - Discontinued Products, 2022
- Number of Products under Development for Glioblastoma Multiforme (GBM), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- 4D Pharma Plc
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Aadi Bioscience Inc
- AB Pharma Ltd
- AbbVie Inc
- Ability Pharmaceuticals SL
- ABM Therapeutics Inc
- Accendatech Co Ltd
- Acomhal Research Inc
- Actuate Therapeutics Inc
- Acura Nanomedicine Inc
- ADCendo ApS
- Adlai Nortye Biopharma Co Ltd
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- Adze Biotechnology Inc
- Aettis Inc
- Affimed GmbH
- Agenus Inc
- AiVita Biomedical Inc
- Akeso Inc
- Alaunos Therapeutics Inc
- Alphageneron-Pharmaceuticals Inc
- Alterity Therapeutics Ltd
- Amal Therapeutics SA
- Amasa Technologies Inc
- Ambrx Biopharma Inc
- Anagenics Ltd
- Annji Pharmaceutical Co Ltd
- Apac Biotech Pvt Ltd
- Apexigen Inc
- APIM Therapeutics AS
- Apmonia Therapeutics SAS
- Apogenix AG
- Apollomics Inc
- Aptamer Sciences Inc
- Arcus Biosciences Inc
- Argonaut Therapeutics Ltd
- Arrien Pharmaceuticals LLC
- Arrogene Inc
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Athenex Inc
- Aucentra Therapeutics Pty Ltd
- AUM Biosciences Pte Ltd
- Avalia Immunotherapies Ltd
- Avesthagen Ltd
- Aveta Biomics Inc
- Baobab AiBIO Co Ltd
- Bayer AG
- Beactica Therapeutics AB
- BeiGene Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- Bellicum Pharmaceuticals Inc
- BenevolentAI Ltd
- Berg LLC
- BerGenBio ASA
- Beta Pharma Inc
- Bexion Pharmaceuticals LLC
- BeyondBio Inc
- Bicara Therapeutics Inc
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- Bioasis Technologies Inc
- BioEclipse Therapeutics Inc
- BioIntegrator
- BioNTech SE
- Biorchestra Co Ltd
- Biovista Inc
- BioXpress Therapeutics SA
- Black Diamond Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Boryung ViGenCell Inc
- BoYuan RunSheng Pharma Hangzhou Co Ltd
- Breakpoint Therapeutics GmbH
- Bristol-Myers Squibb Co
- Candel Therapeutics Inc
- Cantex Pharmaceuticals Inc
- Carina Biotech Pty Ltd
- CARsgen Therapeutics Ltd
- Cell Medicine Cooperation
- Cellatoz Therapeutics Inc
- CellCure
- Celldex Therapeutics Inc
- Cellestia Biotech AG
- Cellis AG
- Cellivery Therapeutics Inc
- Cellworks Group Inc
- Celros Biotech Co Ltd
- Century Therapeutics Inc
- Chemestmed OU
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chimeric Therapeutics Ltd
- Chimerix Inc
- Clarity Pharmaceuticals Ltd
- Cloaked Therapeutics LLC
- Clonz Biotech Pvt Ltd
- CNS Pharmaceuticals Inc
- Codiak BioSciences Inc
- Cothera Bioscience Pty Ltd
- Cotinga Pharmaceuticals Inc
- Curative Biotechnology Inc
- CureLab Oncology Inc
- Curevac NV
- Curigin Co Ltd
- Curtana Pharmaceuticals Inc
- Cynata Therapeutics Ltd
- Cytix Inc
- Cytodyn Inc
- Cytonus Therapeutics Inc
- Cytovia Holdings Inc
- Daiichi Sankyo Co Ltd
- Dalriada Therapeutics Inc
- DEKK-TEC Inc
- Denovo Biopharma LLC
- DevaCell Inc
- Diakonos Research Ltd
- Diverse Biotech Inc
- Divide and Conquer Ltd
- DNAtrix Inc
- DynamiCure Biotechnology LLC
- Edison Oncology Holding Corp
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Elicera Therapeutics AB
- Elpis Biopharmaceuticals Corp
- ENB Therapeutics LLC
- EnduRx Pharmaceuticals Inc
- Enochian Biosciences Inc
- EntreChem SL
- Enveric Biosciences Inc
- EpicentRx Inc
- EpiDrugs Discovery
- Epigene Therapeutics Inc
- ERC Belgium SA
- ERYTECH Pharma SA
- Etirarx LLC
- Eutilex Co Ltd
- Ever Supreme Bio Technology Co Ltd
- Everfront Biotech Inc
- Evgen Pharma Plc
- Exopharm Ltd
- F. Hoffmann-La Roche Ltd
- Falcon Therapeutics Inc
- Felicitex Therapeutics Inc
- Flag Therapeutics Inc
- Flavocure Biotech LLC
- Fore Biotherapeutics Inc
- Fujifilm Holdings Corp
- Galapagos NV
- Gan & Lee Pharmaceuticals Co Ltd
- Gedeon Richter Plc
- Geneius Biotechnology Inc
- Genenta Science SpA
- Genentech USA Inc
- Geneos Therapeutics Inc
- Genexine Inc
- Genisphere LLC
- Genomefrontier Therapeutics Inc
- Genor BioPharma Co Ltd
- Genoscience Pharma
- Gilead Sciences Inc
- GlioCure SAS
- Glycostem Therapeutics BV
- GlyTherix Ltd
- GSK plc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangxi Hebabiz Pharmaceutical Co Ltd
- HaimBio Ltd
- Hamlet Pharma AB
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Hebei Senlang Biotechnology Co Ltd
- Hemispherian AS
- HOX Therapeutics Ltd
- Humanigen Inc
- Hunan Siweikang Therapeutics Ltd
- Hutchison MediPharma Ltd
- i2 Pharmaceuticals Inc
- Ibex Biosciences LLC
- Immatics NV
- Immix BioPharma Inc
- ImmPACT Bio USA Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Immunitor Inc
- ImmunityBio Inc
- ImmunoAct Pvt Ltd
- Immunomic Therapeutics Inc
- Implicyte Inc
- Imunon Inc
- IMV Inc
- Imvax Inc
- IN8bio Inc
- Incyte Corp
- Infinity Pharmaceuticals Inc
- Ingenew Pharmaceuticals Inc
- Inovio Pharmaceuticals Inc
- Inspirna Inc
- Instituto Biomar SA
- IntelliStem Technologies Inc
- Intensity Therapeutics Inc
- InterLeukin Combinatorial Therapies Inc
- InteRNA Technologies BV
- Invectys SA
- Isarna Therapeutics GmbH
- Istari Oncology Inc
- ITM Isotope Technologies Munich SE
- J Ints Bio Co Ltd
- JenKem Technology Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- JW CreaGene Co Ltd
- Kalgene Pharmaceuticals Inc
- Kancera AB
- Kartos Therapeutics Inc
- Karus Therapeutics Ltd
- Karyo Biologics LLC
- Karyopharm Therapeutics Inc
- Kazia Therapeutics Ltd
- Kidswell Bio Corp
- Kintara Therapeutics Inc
- Komipharm International Co Ltd
- Kringle Pharma Inc
- Lacerta Therapeutics Inc
- Laminar Pharmaceuticals SA
- Lantern Pharma Inc
- Lauren Sciences LLC
- LeadInvent Pharma Inc
- Legend Biotech Corp
- Lentigen Technology Inc
- Liangjiang Medicine Co Ltd
- Lin Bioscience Inc
- Luminus Biosciences Inc
- Lumos Pharma Inc
- Luye Pharma Group Ltd
- MacroGenics Inc
- MAIA Biotechnology Inc
- Matrix Biomed Inc
- Medesis Pharma SA
- Medical Guidance Systems LLC
- Medicenna Therapeutics Corp
- Medicon Pharmaceuticals Inc
- Medisun Precision Medicine Ltd
- MedPacto Inc
- Mepsgene Co Ltd
- Mercaptor Discoveries Inc
- Merck & Co Inc
- Merck KGaA
- Meryx Inc
- Metis Precision Medicine
- MetVital Inc
- MGC Pharmaceuticals Ltd
- Midatech Pharma Plc
- Millennium Pharmaceuticals Inc
- MimiVax LLC
- Mina Therapeutics Ltd
- MiReven Pty Ltd
- Molecular Targeting Technologies Inc
- Moleculin Biotech Inc
- Mustang Bio Inc
- Mycenax Biotech Inc
- Myeloid Therapeutics Inc
- Myosin Therapeutics Inc
- Myrio Therapeutics Pty Ltd
- Nanjing Aimeifei Biomedical Technology Co Ltd
- Nanjing CART Medical Technology Co Ltd
- Nanjing KAEDI Biotech Inc
- Nanocan Therapeutics Corp
- NanoCarrier Co Ltd
- Nanomerics Ltd
- NanoPharmaceuticals LLC
- Nascent Biotech Inc
- NatureWise Biotech & Medicals Corp
- NeoTX Therapeutics Ltd
- Neuropore Therapies Inc
- NewG Lab Pharma Inc
- NGM Biopharmaceuticals Inc
- NH TherAguix SAS
- Northlake International LLC
- Northwest Biotherapeutics Inc
- Nostrum Biodiscovery SL
- Novartis AG
- Noxopharm Ltd
- Nuvalent Inc
- NuvOx Pharma LLC
- Nyrada Inc
- Oblato Inc
- Ocean Biomedical Inc
- OGD2 Pharma SAS
- Oleolive LLC
- Omniox Inc
- Oncodesign SA
- Oncolytics Biotech Inc
- Onconova Therapeutics Inc
- OncoResponse Inc
- Oncorus Inc
- OncoRx Pharmaceuticals Inc
- Oncotelic Therapeutics Inc
- Oncoteq AG
- OncXerna Therapeutics Inc
- OneChain Immunotherapeutics
- Ono Pharmaceutical Co Ltd
- Origenis GmbH
- Orphelia Pharma SAS
- Ossianix Inc
- Otsuka Pharmaceutical Co Ltd
- Ovensa Inc
- Palisades Therapeutics
- Parabon NanoLabs Inc
- Pascal Biosciences Inc
- Patrys Ltd
- PENAO Pty Ltd
- Peptomyc SL
- Pfizer Inc
- Phanes Therapeutics Inc
- Pharma Mar SA
- PharmAbcine Inc
- PharmCADD Co Ltd
- Philogen SpA
- Phoenix Biotechnology Inc
- Phost'IN SAS
- Photolitec LLC
- Photonamic GmbH & Co KG
- Pinotbio Inc
- Plex Pharmaceuticals Inc
- Plexxikon Inc
- Polaris Pharmaceuticals Inc
- PolyPid Ltd
- Praesidia Biotherapeutics Inc
- Prelude Therapeutics Inc
- Prescient Therapeutics Ltd
- Preveceutical Medical Inc
- Primevax Immuno Oncology Inc
- PTC Therapeutics Inc
- Puma Biotechnology Inc
- QED Therapeutics Inc
- Quadriga BioSciences Inc
- Qualigen Therapeutics Inc
- R-Pharm
- Radiopharm Theranostics Ltd
- Refuge Biotechnologies Inc
- Regeneron Pharmaceuticals Inc
- Reglagene Holding Inc
- Regulus Therapeutics Inc
- ReNeuron Group Plc
- Ridgeline Therapeutics LLC
- Rottapharm Biotech Srl
- Rznomics Inc
- Safe Save Medical Cell Sciences & Technology Co Ltd
- Sagimet Biosciences Inc
- Salarius Pharmaceuticals Inc
- Sano Chemicals Inc
- Sanofi
- Sapience Therapeutics Inc
- Sentinel Oncology Ltd
- Serb SAS
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai HyaMab Biotech Co Ltd
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Shanghai YaKe Biotechnology Co Ltd
- Shenzhen BinDeBio Ltd
- Shenzhen Zhenxing Pharmaceutical Technology
- Shuttle Pharmaceuticals Inc
- SideROS
- SignPath Pharma Inc
- Silenseed Ltd
- Singh Biotechnology LLC
- SixFold Bioscience Ltd
- SK Life Science Inc
- SL Bigen Co Ltd
- SL VaxiGen Inc
- Spectrum Pharmaceuticals Inc
- Speer Medical Technologies LLC
- STAT3 Therapeutics Inc
- StemGen SpA
- StemVax LLC
- Suntec Medical (Taiwan) Inc
- Susavion Biosciences Inc
- Suzhou JiSheng Pharmaceutical Co Ltd
- Suzhou Stainwei Biotech Inc
- Synactix Pharmaceuticals Inc
- Synchronicity Pharma Inc
- Synergys Biotherapeutics Inc
- SyntheX Inc
- Tactical Therapeutics Inc
- TAE Life Sciences LLC
- Taiho Oncology Inc
- Tango Therapeutics Inc
- Targinta AB
- TargTex SA
- TC BioPharm Ltd
- Telo Therapeutics Inc
- Telomium SAS
- The Palo Alto Research Center
- TheraBiologics Inc
- TheraBioPharma Inc
- Theralase Technologies Inc
- Therapeia GmbH & Co KG
- Titan Pharmaceuticals Inc
- TME Pharma AG
- Tmunity Therapeutics Inc
- Transcode Therapeutics Inc
- Transtarget Inc
- Trevarx Biomedical Inc
- Triterpenoid Therapeutics Inc
- Turning Point Therapeutics Inc
- TVAX Biomedical Inc
- Tyme Inc
- U-Cell Therapeutics Pte Ltd
- Up Therapeutics Inc
- UTC Therapeutics Inc
- Vault Pharma Inc
- VBI Vaccines Inc
- VCN Biosciences SL
- Vect-Horus SAS
- Verismo Therapeutics
- Vigeo Therapeutics Inc
- Vivace Therapeutics Inc
- Voronoi Group
- Vyro Bio Inc
- Wayshine Biopharma Inc
- Wigen Biomedicine Technology (Shanghai) Co Ltd
- WindMIL Therapeutics Inc
- WPD Pharmaceuticals Inc
- Wuhan Binhui Biotechnology Co Ltd
- X4 Pharmaceuticals Inc
- Xequel Bio Inc
- Xi'An Yufan Biotechnology Co Ltd
- Xonovo Inc
- Yooyoung Pharm Co Ltd
- Yuhan Corp
- Yumanity Therapeutics Inc
- Zata Pharmaceuticals Inc
- Zentalis Pharmaceuticals Inc
- ZhongSheng BioTech Inc
- Zumutor Biologics Inc
